Charles River Laboratories
CRL
612 hedge funds and large institutions have $10.7B invested in Charles River Laboratories in 2023 Q2 according to their latest regulatory filings, with 67 funds opening new positions, 252 increasing their positions, 203 reducing their positions, and 73 closing their positions.
24% more repeat investments, than reductions
Existing positions increased: 252 | Existing positions reduced: 203
5% more capital invested
Capital invested by funds: $10.3B → $10.7B (+$474M)
0.21% less ownership
Funds ownership: 100.16% → 99.94% (-0.21%)
8% less first-time investments, than exits
New positions opened: 67 | Existing positions closed: 73
1% less funds holding
Funds holding: 620 → 612 (-8)
16% less call options, than puts
Call options by funds: $29.3M | Put options by funds: $34.8M
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| 1 |
BlackRock
New York
|
+$81.8M |
| 2 |
AI
Ariel Investments
Chicago,
Illinois
|
+$72.6M |
| 3 |
ClearBridge Investments
New York
|
+$68.3M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$50.8M |
| 5 |
MBI
Montrusco Bolton Investments
Montreal,
Quebec, Canada
|
+$43.7M |
Top Sellers
CRL Hedge Fund Activity: Q2 2023 in Review
612 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Charles River Laboratories (CRL) for Q2 2023, worth a combined $10.7B — up 4.6% from $10.3B a quarter earlier.
Sellers outnumbered buyers: 73 funds closed out of CRL and 67 opened new positions — a net loss of 6 holders — while 203 trimmed existing stakes and 252 added.
The largest buyer was BlackRock, adding an estimated $81.8M. The largest seller was Marshall Wace, cutting an estimated $105M.
- 612 institutional investors held Charles River Laboratories (CRL) as of Q2 2023, down from 620 in Q1 2023.
- Funds reported $10.7B of Charles River Laboratories stock for Q2 2023, up 4.6% quarter-over-quarter.
- 67 funds opened new Charles River Laboratories positions in Q2 2023 and 73 closed out, a net change of -6 holders.
- The largest Charles River Laboratories buyer in Q2 2023 was BlackRock, an estimated $81.8M added.
- The largest Charles River Laboratories seller in Q2 2023 was Marshall Wace, an estimated $105M sold.
Based on aggregated 13F filings for Q2 2023.